Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -24M | -17M | -20M | -16M | -8M |
| EBITDA | -24M | -23M | -20M | -16M | -12M |
| Net Income | -22M | -23M | -20M | -16M | -13M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$1.37
-1.80% today
Window Change
-0.72%
Window
May 29, 2026 → Jun 22, 2026
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 16 bars · May 29, 2026 → Jun 22, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
MAIA Biotechnology, Inc. (MAIA) is a Healthcare stock with a market cap of $50.00M and listed on AMEX. The stock last traded around $1.36 and down 0.7% across the available one-year price window (May 29, 2026 → Jun 22, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +33.3%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +33.3%, free cash flow -20.0% with operating margin 0.0% and ROIC -0.6%. Stock Foundry combines MAIA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
MAIA
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
MAIA Max Drawdown
-15.33%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for MAIA and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$12.5M
+20.7% YoY
Free Cash Flow
-$4.1M
+65.9% YoY
Revenue Growth
+0.0%
EPS Growth
+33.3%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -24M | -17M | -20M | -16M | -8M |
| EBITDA | -24M | -23M | -20M | -16M | -12M |
| Net Income | -22M | -23M | -20M | -16M | -13M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 8.7B | 10M | 7M | 11M | 11M |
| Total Assets | 10M | 10M | 8M | 12M | 11M |
| Total Liabilities | 7M | 7M | 7M | 4M | 2M |
| Shareholder Equity | 2M | 4M | 478K | 9M | 9M |
| Total Debt | 0 | 0 | 0 | 0 | 0 |
| Net Debt | -8.7B | -10M | -7M | -11M | -11M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
4M
+65.9% YoY
Capital Expenditures
0
Free Cash Flow
4M
+65.9% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-3.8%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.